63 results about "Arterial occlusion" patented technology

An intravascular catheter system includes an intravascular catheter that can be easily and safely navigated through severely occluded arteries. The system uniquely includes both an optical fiber for use in providing data for guiding the catheter and a conventional metal guide wire for use in navigating the catheter through the artery passageway. The system further includes optical imaging of the arterial occlusion during guidance of the catheter through the artery passageway. More particularly the system provides a visual indication to the surgeon to determine if the catheter assembly is approaching the arterial wall.

A method and system for use in measuring the endothelial dysfunction utilizing flow mediated dilation and determining arterial health of a patient. The system includes a non-invasive blood pressure monitor, an ultrasound system and a pulse oximeter monitor that all communicate with each other to perform the flow mediated dilation. Initially, the ultrasound transducer, blood pressure cuff and pulse oximeter sensor are positioned on an arm of the patient. The blood pressure cuff is inflated to occlude an artery for an occlusion period. Following the occlusion period, the ultrasound system is automatically signaled to begin determining a parameter of the artery, such as diameter, and the flow rate of blood through the artery without any operator intervention. At the same time, the pulse wave velocity PWV is calculated between the ultrasound transducer and the finger probe of the pulse oximeter following the occlusion period. Based upon the detected characteristics of the artery before and after occlusion, as well as the PWV, the system can determine the endothelial dysfunction and arterial health of the patient.

Non-permanent occlusion of the uterine arteries is sufficient to cause the demise of uterine myomata without unnecessarily exposing other tissues and anatomical structures to hypoxia attendant to prior permanent occlusion techniques. A therapeutically effective transient time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 hours to 24 hours, and preferably is at least about 4 hours. A therapeutically effective temporary time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 day (24 hours) to 7 days (168 hours), and preferably is about 4 days (96 hours). By invaginating the tissues of the vaginal wall up to or around a uterine artery, collapse of the uterine artery can be achieved without penetrating tissue of the patient.

A treatment procedure is disclosed which involves the short term, non-permanent occlusion of the patient's blood vessels by depositing a bioabsorbable embolic mass within the patient's blood vessel. The procedure is particularly suitable for treating uterine disorders by occluding a patient's uterine arteries. A therapeutically effective time period for occlusion of a uterine artery is from about 0.5 to about 48 hours, preferably about 1 to about 24 hours, with occlusion times of about 1 to about 8 hours being suitable in many instances. The embolic mass may bioabsorbable particulate with minimum transverse dimensions of about 100 to about 2000 micrometers, preferably about 300 to about 1000 micrometers. The particulate may be a polymeric material formed of polylactic acid, polyglycolic acid or copolymers thereof, or a swellable copolymer of lactic acid and polyethylene glycol. The embolic material may be delivered to an intracorporeal site as a biocompatible solution containing a solute which is relatively insoluble in a water based fluid and a solvent which is relatively soluble in the water based fluid, where the solute forms the embolic mass which occludes or partially occludes a body lumen or fills or partially fills a body cavity.

Method to obtain continuous recording of the central arterial blood pressure waveform noninvasively utilizes dual (distal occlusion and proximal) brachial artery occlusion cuffs and dual external osculation. The distal arterial occlusion cuff eliminates venous stasis artifact and flow related gradient from aorta to the brachial artery. The proximal cuff measures, and delivers, dual external oscillation. The dual external oscillation allows measurement of the arterial compliance at a multitude of transmural pressure values during each cardiac cycle. Transmural pressure / arterial compliance and arterial pressure curves are subsequently reconstructed using dual external oscillation. The curves consist of two parts, rapid and slow parts, both at the frequency higher than the arterial pulse.

The invention discloses an instrument for arterial occlusion lesion treating and the application thereof. The instrument comprises a vascular ultrasound catheter, a treating micro catheter and a treating guiding line. The vascular ultrasound catheter and the treating micro catheter are integrally connected in parallel. One part of the treating guiding line is placed in the treating micro catheter, and the other part of the treating guiding line penetrates out of the treating micro catheter from a side wall outlet. According to the instrument, the vascular ultrasound catheter and the treating micro catheter are integrally connected in parallel, a double-cavity micro catheter is used for adjusting the treating guiding line to enter a vessel true lumen, thrombus is sucked out through the treating guiding line, and post-operation hidden danger is removed through one-time curing. The problem that in an intervention recanalization treating operation of blocking of coronary arteries, peripheral arteries and other organ pipelines, a treating guiding line cannot enter a true lumen easily is solved.

The invention relates to prostaglandin microemulsion-gel preparation and a preparation method thereof. The preparation comprises prostaglandin E1 or the derivative thereof, oil, emulsifier, assistant for emulsifying agent, gel substrate and water, and also possibly comprises a permeation accelerator, a preparation stabilizer, an antioxidant and antiseptics. The preparation has the advantages of good percutaneous permeability, no stimulation to skin and mucous membrane, simple preparation technique and stable quality, the preparation can be used for treating diseases such as ulcer of limbs caused by erectile dysfunction and chronic arterial occlusion and rest pain of limbs caused by microcirculatory disturbance.

The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronic fibrotic occlusion, chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme containing formulation. A method is provided for treating chronically occluded animal tubes and cavities by administering a therapeutic effective amount of a proteolytic enzyme-containing formulation adjacent to an occluding atherosclerotic plaque, waiting for a pre-angioplasty waiting period, followed by crossing the plaque with an angioplasty guide wire.

The invention provides phascolosoma esculenta plasmin, which is extracted from phascolosoma esculenta, and has double activities of directly dissolving fibrin and kinase. The phychemical performance of the plasmin is that: the molecular weight is between 28,000 and 32,000, the isoelectric point is between 4.6 and 6.6, the dissolution activity of fibrin does not change greatly under a temperature range between 30 and 70 DEG C, and the stability range to the pH value is between 5.0 and 9.0. The phascolosoma esculenta plasmin has the direct fibrin and kinase dissolving activities, has simple extracting process, low preparation cost and easily obtained raw materials, can be developed into intravenous injection, contains the plasmin capable of directly dissolving thrombus, and is expected to obtain better effect in treating catheter assisted thrombolysis treating peripheral arterial occlusion and deep venous thrombosis.

The invention relates to an auxiliary bandaging device for an elastic bandage, and belongs to the technical field of medical equipment. The auxiliary bandaging device is used for the postoperative hemostasis bandaging of the elastic bandage, and is characterized by comprising an upper fixing plate and a lower fixing plate, wherein the upper fixing plate is placed at a waist, the inner lateral surface of the upper fixing plate imitates the shape of the waist, and the outer lateral surface of the upper fixing plate is provided with salient points, grooves, fixing holes or sheaths; the lower fixing plate is placed outside thighs, the inner lateral surface of the lower fixing plate imitates the shapes of the thighs, and the outer lateral surface of the lower fixing plate is provided with salient points, grooves, fixing holes or sheaths; and the auxiliary bandaging device also comprises a front fixing plate an a rear fixing plate according to actual requirements. After patients do operation, the elastic bandage winds on the auxiliary bandaging device, so that the elastic bandage can be prevented from sliding and curling effectively; and compared with the conventional bandage hemostasis method, the auxiliary bandaging device has the advantage that after the auxiliary bandaging device is adopted, the bandage is not tied in flesh, so that the pain of the patients is relieved effectively. By using the auxiliary bandaging device for the elastic bandage, pressure can be reduced at any time according to actual requirements, so that the arterial occlusion of lower limbs and deep venous thrombosis of the patients are avoided.

Disclosed are a vascular disease examination system capable of examining and diagnosing vascular diseases such as arterial obliteration by determining the feature quantities of blood flow velocity waveforms or blood pressure waveforms or blood flow rates, and a bypass vascular diagnosing system. A blood flow velocity or blood pressure at a target location of the body is measured A waveform analysis unit 4 determines the feature quantity of a blood flow waveform (or blood pressure waveform), for displaying on an output unit 5. The feature quantity includes a time constant, Fourier transform value, differentiated value, integrated value, rise / fall time, and sharpness or gradient of rise. Feature quantity of a blood flow velocity waveform (or blood pressure waveform) indicated in numeric value enables a correct examination / diagnosis.

Featured are methods for non-invasive assessment of vascular reactivity. The methods of the invention use phase contrast magnetic resonance imaging angiography and use the image data thereby acquired to measure shear rate, radius of the vasculature and flow through the vasculature. According to one aspect, such acquisition of image data occurs before and during, an arterial occlusion and according to another aspect such acquisition of image data occurs before during and after arterial occlusion. The disclosed methods of the invention allow for reproducible, non-invasive diagnosis of early stage indicators of atherosclerosis.

A method for digital thermal monitoring assessment of vascular function comprising a temporary arterial occlusion using a pneumatic cuff positioned on a subject's upper limb, monitoring skin temperature at the fingertip of the occluded limb for a period of time before, during, and after the occlusion, calculating a Zero Reactivity Curve based on variables including start temperature, room temperature, and the slope of temperature decline during the occlusion, and assessing vascular function based on comparing the Zero Reactivity Curve and the observed temperature rebound after the occlusion is removed. A vascular reactivity monitoring apparatus for measuring skin surface temperature comprising an inflatable cuff for placement around a subject's limb, a digital thermal measuring device and photoplethysmography measuring device for placement on a finger of the subject's limb wearing the cuff and a second digital monitoring device and photoplethysmography measuring device for placement on a finger of the subject's contralateral limb.

Devices, and methods for synchronizing cerebro-hemodynamic signals are disclosed. In one aspect, the devices and methods may include synchronizing first and second signals indicative of hemodynamic characteristics within a subject's brain. Differences may be determined between the synchronized signals and used to provide information for diagnosing changes in arterial occlusion. Differences between the synchronized signals may include differences, such as timing delays, between signature features of the synchronized signals. The first and second signals may be indicative of hemodynamic characteristics in first and second hemisphere's of a subject's brain. The first and second signals may be bioimpedance signals.

The invention relates to sipunculus nudus plasmin which is extracted from sipunculus nudus and has double activities of directly dissolving fibrin and kinase. The sipunculus nudus has the materialization performances that the molecular weight ranges from 27000 to 35000, the isoelectric point ranges from 4.5 to 7.0, the dissolving activity of fibrin varies little within the temperature range of 30 to 70 degrees centigrade, and the stability range of the pH value ranges from 5.0 to 9.0. The sipunculus nudus plasmin has double activities of directly dissolving the fibrin and the kinase, simple extraction process, low preparation cost and easily obtained materials, can be developed into vein injection, contains the plasmin for directly degrading thrombus and is expected to have better effect on treating periphery arterial occlusion and deep vein thrombosis in a conduit-assisted thrombolytic therapy.

A method and system for use in measuring the endothelial dysfunction utilizing flow mediated dilation and determining arterial health of a patient. The system includes a non-invasive blood pressure monitor, an ultrasound system and a pulse oximeter monitor that all communicate with each other to perform the flow mediated dilation. Initially, the ultrasound transducer, blood pressure cuff and pulse oximeter sensor are positioned on an arm of the patient. The blood pressure cuff is inflated to occlude an artery for an occlusion period. Following the occlusion period, the ultrasound system is automatically signaled to begin determining a parameter of the artery, such as diameter, and the flow rate of blood through the artery without any operator intervention. At the same time, the pulse wave velocity PWV is calculated between the ultrasound transducer and the finger probe of the pulse oximeter following the occlusion period. Based upon the detected characteristics of the artery before and after occlusion, as well as the PWV, the system can determine the endothelial dysfunction and arterial health of the patient.

A thrombolysis catheter apparatus is disclosed comprising: (a) an elongated thrombolysis catheter portion comprising a plurality of independently controllable electroactive polymer actuators, which provide a curvature to the thrombolysis catheter based upon received control signals; (b) a control unit coupled to the plurality of actuators and sending the control signals to the plurality of actuators; and (c) an occlusion removal device. Also disclosed is a method of treating an arterial occlusion by advancing the thrombolysis catheter portion through the arterial vasculature of a patient to a position proximate the occlusion, while controlling the shape of the thrombolysis catheter portion using the control unit. The occlusion is then removed using the occlusion removal device.

The invention discloses a blood flow guiding dense net stent. The dense net stent is formed by a plurality of independent net pipe stents. A plurality of multiple independent net pipe stents can penetrate through one another to form an independent net pipe stent, and the independent net pipe stent is formed by weaving metal wires, anti-thrombus polymer fibers and polymer fibers for promoting endothelialization of vascular cells; when used for interventional therapy of aneurysm, the blood flow guiding dense net stent has good anti-thrombus and endothelialization promotion performance of a cardiovascular stent, and the diameter of the stent meshes is gradually increased along with gradual closure of the aneurysm and vascular reconstruction, so that artery occlusion of perforator and collateral branches in a coverage area of the interventional stent can be effectively prevented; the safety and effectiveness of vascular reconstruction are greatly improved; meanwhile, due to the fact that the metal wires with different diameters and the polymer fibers are used, the dense net stent is rigid and soft, good radial supporting force can be kept, and safety and effectiveness of the stent are further guaranteed; and the stent is simple in preparation process and low in cost, and can be used for automatic production.

A method and system for use in measuring the endothelial dysfunction in a patient utilizing flow mediated dilation. The system includes both a non-invasive blood pressure monitor and an ultrasound system that communicate with each other to perform the flow mediated dilation. Initially, the ultrasound transducer and blood pressure cuff are positioned on an arm of the patient and the blood pressure cuff is inflated to occlude an artery for an occlusion period. Following the occlusion period, the ultrasound system is automatically signaled to begin determining both the diameter of the artery and the flow rate of blood through the artery without any operator intervention. Based upon the detected characteristics of the artery before and after occlusion, the system can determine the endothelial dysfunction of the patient.

The invention relates to an integrated stent for an aortoiliac artery. The integrated stent comprises a metal stent and a lamination layer on the metal stent, the metal stent comprises a main portion, a first branch portion and a second branch portion to form an integrated Y shape matched with an inner cavity shape of the aortoiliac artery, and the main portion, the first branch portion and the second branch portion are communicated with one another. The metal stent is a tubular stent formed by braiding of metal wires. Instead of previous split stents used in the aortoiliac artery, the integrated stent for the aortoiliac artery is an integrated stent for treatment in occlusive cavity of the aortoiliac artery; owing to integration of the main portion, the first branch portion and the second branch portion, the whole stent is steady and prevented from displacement under high-speed blood impact; in addition, due to a large aortoiliac artery occlusive lesion range, the integrated stent guarantees complete isolation of lesions without influences on subsequent far-end lesion intra-cavity treatment on the premise of safe and effective release.

Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model under conditions of transient or permanent total arterial occlusion. These studies also disclose that when the neurodegeneration is caused by ischemic stroke, combining the administration of a selected NCS-01 cell population with thrombolytic agents and / or mechanical methods of clot removal leads to a decrease in the volume of infarction caused by acute onset neurodegeneration. The disclosed cell therapy promises to make a significant clinical impact on patient survival after stroke.

The invention belongs to the technical field of medicament, and discloses a bilobalide and a use of derivative thereof in treating encephaledema, especially encephaledema caused by cerebral ischemia. Research results show that the bilobalide can reduce the brain tissue water content and the cerebral infarction area of a permanent medium-sized arterial occlusion model animal. The mechanism of the bilobalide for weakening the formation of encephaledema is to lower the mRNA transcription level of aquaporin 1, 4 and 9 and the expression level of protein in different stages. The bilobalide can be combined with a pharmaceutically acceptable carrier to be prepared into a clinically acceptable injection, a transdermal preparation or an oral administration preparation for treating the encephaledema.

The invention discloses a method for evaluating collateral vessels and tissue function based on cerebral blood flow, which comprises the following steps of: firstly, registering cerebral blood flow graphs with multiple delay times of a patient diagnosed with major artery occlusion infarction to realize one-to-one correspondence on a spatial anatomical structure; secondly, removing cerebral shellsand extracerebral structures of the cerebral blood flow graphs with multiple delay times after registration, and calculating cerebral blood flow difference graphs with multiple delay times; then, visualizing cerebral collateral blood circulation conditions, and quantifying collateral blood flow related information, such as collateral blood flow distribution range, velocity, flow and the like; andfinally, by combining with the infarction core area of the patient diagnosed with the major artery occlusion infarction, evaluating the ischemic penumbra, such as the size, volume and position of theischemic penumbra.

The invention is directed to methods for angiotyping individual patients to predict the likelihood of whether a given individual will develop good vs. poor collaterals naturally. Accordingly, this can involve obtaining and providing a list of genes involved in collateral development. In particular, angiotyping individual patients can be used to predict the likelihood of whether a given individual will develop good vs. poor collaterals in response to specific angiogenesis therapy. From an array of genes that have been determined through experimental studies as being differentially expressed in tissues in which collaterals are developing in response to arterial occlusion, single nucleotide polymorphisms (SNPs), or other epigenetic changes, such as DNA methylation patterns, can be identified. SNPs and DNA methylation patterns are detected using microchips or similar technology assaying for all, or most, of the genes determined to play a role in collateral development. In addition, abnormally low or abnormally high differential expression of any combination of the candidate genes can be detected in such tissue as peripheral blood cells. The presence of a predisposition to develop poor vs. good collaterals is indicated by the presence of SNPs, and / or alterations in DNA methylation patterns, and / or difference in expression levels involving one or more of the genes.

The invention provides a femoral artery puncture suture device. The installing end of a needle pushing tube is installed in the middle of an arc-shaped puncture needle. Two ends of a suture line are respectively fixed to two ends of the arc-shaped puncture needle. The middle of the suture line is fixed to the operating end of the needle pushing tube. The arc-shaped puncture needle is made from memory alloy. The arc-shaped puncture needle is arranged in a catheter sheath, and needle points at two ends are in inward stress-compressed shapes. When the needle pushing tube pushes the arc-shaped puncture needle output of the catheter sheath, the needle points at the two ends of the arc-shaped puncture needle are outwards released to be in memory shapes. The arc-shaped puncture needle of the femoral artery puncture suture device is put in a femoral artery puncture port by using the memory alloy and penetrates out from inside to outside, the suture line penetrates out, accordingly inner diaphragm floating caused by artery atherosclerotic plaque lifting due to threading from outside to inside is avoided, interlayer and secondary thrombosis formation possibly occurred under blood impact is avoided, and accordingly the complication of arterial occlusion is avoided.

The present invention relates to an apparatus to assist binding of an elastic bandage, used to bind an elastic bandage to stop bleeding. The apparatus comprises: at least one upper fixing plate and at least one lower fixing plate, wherein the upper fixing plate is to be placed on the waist, the inside face being shaped like the waist; the lower fixing plate is to be placed on the outside of the thigh, the inside face being shaped like the thigh; and the upper fixing plate and the lower fixing plate both also have an outside face used to make contact with the elastic bandage, to prevent the elastic bandage from slipping and twisting. After a patient has undergone surgery, the elastic bandage is wound on the apparatus to assist binding and can effectively prevent the elastic bandage from slipping and twisting. In comparison with conventional methods of stopping bleeding with bandages, after using the apparatus to assist binding, the bandage will not cut into the flesh, effectively lessening the pain felt by the patient. Using the apparatus to assist binding of an elastic bandage of the present invention allows pressure to be reduced at all times according to practical needs, preventing arterial occlusion of the lower extremities and deep vein thrombosis occurring in the patient.

The present invention relates to a method for generating a non-human model animal of an arterial occlusive disease, wherein the method is characterized in that an artery is occluded at a specific site by ligating it or with an autologous blood clot. In particular, the present invention relates to a method and a kit for generating a cardiac infarction model, as well as a cardiac infarction animal model obtained by employing the method or kit, characterized in that in a non-human experimental animal, a blood vessel is ligated downstream of an arterial site of the heart to be occluded, followed by occluding the artery at said site. In addition, the present invention also relates to a method and a system for generating a non-human animal model of arterial embolus, as well as an arterial embolus animal model obtained by employing the method or system, characterized by adding an coagulating agent to autologous blood to form an autologous blood clot and subsequently employing an angiographic apparatus in delivering the autologous blood clot into an artery.